North Chicago-based drugmaker AbbVie must pay back Medicare for raising the price of its blockbuster drug Humira too quickly, the federal government said Wednesday. The penalty follows years of ...

Seven new alternatives to the high-cost Humira drug will be available in July. Some will be offered at significantly lower prices, but will patients see big savings? Lowering drug prices for patients ...

Mark Cuban's Cost Plus Drug Company announced a partnership with Coherus BioSciences to offer customers a biosimilar of Humira. Humira, owned by AbbVie Inc, is one of the bestselling drugs of all time ...

Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...

Humira has been one of the world's top selling drugs for more than two decades. But thanks to some new copycats — including one that is being sold at entrepreneur Mark Cuban's online pharmacy — its ...

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor. Alternatives to the world’s ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pharmaceutical giant AbbVie managed to hang on to most of ...

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor. Starting July 1, alternatives to the ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

LAS VEGAS—Optum Rx is planning to add up to three biosimilar drugs to its formulary to compete directly with AbbVie's Humira, which accounts for massive pharmacy spend each year. Optum Rx, the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The first Humira biosimilar hit the U.S. market a little ...